Back to search
FDAFDA · Food and drugs·Recall number D-0193-2023

Apomorphine HCL 2MG/ML (10ML vial) Injectable, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

Published February 1, 2023 · Recall initiated: December 22, 2022

Summary

FDA records drug Class II recall D-0193-2023, published February 1, 2023 and initiated December 22, 2022. Recalling firm: Pharmacy Innovations; Status: Terminated; Reported quantity: N/A; Lot: t20221108@46. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pharmacy Innovations
Distributor
Nationwide in the USA
Lot
t20221108@46
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Apomorphine HCL 2MG/ML (10ML vial) Injectable, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA. recalled?

Yes. FDA published recall D-0193-2023 on February 1, 2023. Reported hazard: Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone